Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, reducing the availability of tetrahydrofolate needed for DNA synthesis. This limits the proliferation of rapidly dividing cells such as immune‑activated lymphocytes and cancer cells, while also increasing extracellular adenosine to dampen inflammation.

The specific dose of Metex is individualized by the prescribing clinician based on the indication, patient weight, renal function and treatment goals. Only a qualified health professional should determine the appropriate regimen.

Methotrexate is classified as teratogenic and is generally contraindicated during pregnancy. It can also be excreted in breast milk, so breastfeeding is not recommended while on therapy unless the prescriber determines the benefits outweigh the risks.

To request Metex, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that can be administered subcutaneously and is generally less costly. It offers broad immunosuppressive activity but may require more laboratory monitoring for hepatic, renal and hematologic safety.

Metex should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and avoid shaking the vial. Keep it in the original packaging until ready for use.

Metex is supplied as a sterile solution for subcutaneous injection. The injection is typically given into the abdomen or thigh using a pre‑filled syringe or vial, following aseptic technique and the dosing schedule prescribed by the treating physician.

Serious risks include severe bone‑marrow suppression leading to infections, liver toxicity that can progress to fibrosis or cirrhosis, and pulmonary complications such as interstitial pneumonitis or fibrosis. Prompt reporting of symptoms like fever, persistent cough, jaundice or unusual bruising is essential.

Metex is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active uncontrolled infections, and in women who are pregnant or planning pregnancy unless the prescriber determines the benefit outweighs the risk.